|
Protocol ID |
Official Title |
PI Name |
Lead CRC |
Disease Site |
Phase |
| CC-16047 ClinicalTrials.gov NCT02834052 | A phase I/II trial of pembrolizumab (MK-3475) and poly-ICLC in patients with metastatic mismatch repair-proficient (MRP) colon cancer | A. Nayak | Kelly Jenkins | Phase 1: All solid tumors, following at least one therapy Phase 2: Mismatch Repair Proficient “MRP” (includes microsatellite stable [MSS] and MSI-low) colon cancer that has progressed following at least two lines of therapy | I/II |
| CC-16053 ClinicalTrials.gov NCT03257722 | A phase Ib /II trial of pembrolizumab and idelalisib in patients with non-small cell lung cancer (NSCLC) who have failed immune checkpoint inhibitor | A. Nayak / Z. Hao | Kelly Jenkins | Non-Small Cell Lung Cancer (NSCLC) | I/II |
| Tesaro 4010-01-001 ClinicalTrials.gov: NCT02715284 | Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors | S. Ghamande | Lisa Marshall & Kelly Jenkins | Solid Tumor | I |
| NLG-2104 ClinicalTrials.gov: NCT02077881 | A Phase 1/2 Study of Indoximond in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas | A. Nayak | Lisa Marshall | Pancreatic Adenocarcinoma | I/II |
| NLG-2105 ClinicalTrials.gov: NCT02502708 | Phase 1 Trials of Indoximod in Combination with Temozolomide-based Therapy for Children with Progressive Primary Brain Tumors | T. Johnson | Robin Dobbins & Kimberly Gray | Pediatric Brain Tumor | I |
| NLG-2106 ClinicalTrials.gov: NCT02835729 | A Phase 1b/Randomized Phase 2a Trial of Indoximod in Combination with Idarubicin and Cytarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) | J. Pantin | Sandra Wall | Acute Myeloid Leukemia (AML) | I/II |
